Strategic partnerships There is a clear pattern of integrations and collaborations with major healthcare and diagnostic players (Quest Diagnostics, Abbott, Paradigm Health, Community Oncology Alliance). This suggests opportunities to target health systems, labs, and CROs for deeper OncoEMR integrations, data collaboration, and joint value propositions around real-world evidence and precision oncology.

Clinical data network Flatiron’s core strength lies in a large cancer-focused clinical data network with OncoEMR and real-world data capabilities. Sales outreach can emphasize expanding site enrollment, broaden data capture, and AI-powered analytics for early detection of treatment patterns and outcomes across community and academic settings.

Expansion readiness Recent activity includes large-scale integrative efforts with labs and health systems, plus a pivot involving asset sales and long-term collaborations. This indicates readiness for scalable deployments, partner-led implementation, and opportunities to offer modular solutions that fit evolving strategic priorities.

Industry engagement Active participation in notable conferences and industry events (ISPOR Annual Meeting) signals ongoing thought leadership and access to market trends. Sales teams can leverage these events for demos, POC discussions, and partnerships centered on real-world evidence, payer insights, and value-based care.

Financial scale Revenue and funding levels position Flatiron as a mid-to-large cap player with substantial enterprise opportunities. Target multi-site health organizations, large oncology networks, and diagnostic groups that require scalable data infrastructure, interoperability, and end-to-end clinical research support to drive efficiency and outcomes.